503 related articles for article (PubMed ID: 30048343)
21. A novel full-human CD22-CAR T cell therapy with potent activity against CD22
Tan Y; Cai H; Li C; Deng B; Song W; Ling Z; Hu G; Yang Y; Niu P; Meng G; Cheng W; Xu J; Duan J; Wang Z; Yu X; Feng X; Zhou J; Pan J
Blood Cancer J; 2021 Apr; 11(4):71. PubMed ID: 33839735
[No Abstract] [Full Text] [Related]
22. Advances in Supportive Care for Acute Lymphoblastic Leukemia.
Cook J; Litzow M
Curr Hematol Malig Rep; 2020 Aug; 15(4):276-293. PubMed ID: 32607955
[TBL] [Abstract][Full Text] [Related]
23. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
[TBL] [Abstract][Full Text] [Related]
24. A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
Jahn L; Hagedoorn RS; van der Steen DM; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(44):71536-71547. PubMed ID: 27689397
[TBL] [Abstract][Full Text] [Related]
25. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Santomasso BD; Park JH; Salloum D; Riviere I; Flynn J; Mead E; Halton E; Wang X; Senechal B; Purdon T; Cross JR; Liu H; Vachha B; Chen X; DeAngelis LM; Li D; Bernal Y; Gonen M; Wendel HG; Sadelain M; Brentjens RJ
Cancer Discov; 2018 Aug; 8(8):958-971. PubMed ID: 29880584
[TBL] [Abstract][Full Text] [Related]
26. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K; Tafuto B; Palladino Kim L; Parrott JS
Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
28. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
29. Efficiency and side effects of anti-CD38 CAR T cells in an adult patient with relapsed B-ALL after failure of bi-specific CD19/CD22 CAR T cell treatment.
Guo Y; Feng K; Tong C; Jia H; Liu Y; Wang Y; Ti D; Yang Q; Wu Z; Han W
Cell Mol Immunol; 2020 Apr; 17(4):430-432. PubMed ID: 31900459
[No Abstract] [Full Text] [Related]
30. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
32. Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity.
Kersten MJ; van Ettekoven CN; Heijink DM
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31722870
[TBL] [Abstract][Full Text] [Related]
33. EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity.
Gust J; Annesley CE; Gardner RA; Bozarth X
J Clin Neurophysiol; 2021 Mar; 38(2):135-142. PubMed ID: 31851018
[TBL] [Abstract][Full Text] [Related]
34. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.
Taraseviciute A; Tkachev V; Ponce R; Turtle CJ; Snyder JM; Liggitt HD; Myerson D; Gonzalez-Cuyar L; Baldessari A; English C; Yu A; Zheng H; Furlan SN; Hunt DJ; Hoglund V; Finney O; Brakke H; Blazar BR; Berger C; Riddell SR; Gardner R; Kean LS; Jensen MC
Cancer Discov; 2018 Jun; 8(6):750-763. PubMed ID: 29563103
[TBL] [Abstract][Full Text] [Related]
36. Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy.
Śliwa-Tytko P; Kaczmarska A; Lejman M; Zawitkowska J
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628334
[TBL] [Abstract][Full Text] [Related]
37. Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy.
Mei H; Jiang H; Wu Y; Guo T; Xia L; Jin R; Hu Y
Br J Haematol; 2018 Jun; 181(5):689-692. PubMed ID: 28369673
[No Abstract] [Full Text] [Related]
38. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
39. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
40. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
